.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,338,846

« Back to Dashboard

Details for Patent: 5,338,846

Title: Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
Abstract:A process for preparing a compounds of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, which comprises reacting a piperazine salt of the formula ##STR2## with an alkyl halide containing compound of the formula ##STR3## in water with a reagent to neutralize the hydrohalic acid and heating the mixture under conditions which are suitable to effect the coupling of said piperazine salt with said alkyl halide containing compound.
Inventor(s): Busch; Frank R. (Gales Ferry, CT), Bowles; Paul (Groton, CT), John; Douglas (New London, CT), Allen; Meldrum (Uncasville, CT), DiRoma; Sabeto A. (Glastonbury, CT), Godek; Dennis M. (Glastonbury, CT)
Assignee: Pfizer Inc. (New York, NY)
Filing Date:Apr 20, 1993
Application Number:08/049,905
Claims:1. A process for preparing a compound of the formula: ##STR7## or a pharmaceutically acceptable acid addition salt thereof, wherein Ar is naphthyl optionally substituted with one to four substituents independently selected from fluoro, chloro, trifluoromethyl, methoxy, cyano and nitro; quinolyl; 6-hydroxy-8-quinolyl; isoquinolyl; quinazolyl; benzoisothiazolyl and an oxide or dioxide thereof, each optionally substituted with one or more substituents independently selected from fluoro, chloro, trifluoromethyl, methoxy, cyano, and nitro; benzothiazolyl; benzothiadiazolyl; benzotriazolyl; benzoxazolyl; benzoxazolonyl; indolyl; indanyl optionally substituted by one or two fluoro; 3-indazolyl optionally substituted by 1-trifluoromethylphenyl; and phthalazinyl;

n is 1 or 2; and

X and Y, together with the phenyl to which they are attached, form a ring system selected from quinolyl; 2-hydroxyquinolyl; benzothiazolyl; 2-aminobenzothiazolyl; benzoisothiazolyl; indazolyl; 2-hydroxyindazolyl; indolyl; spiro[cyclopentane-1,3'-indolinyl]; and oxindolyl; wherein said ring system may optionally be substituted with one to three substituents independently selected from (C.sub.1 -C.sub.3)alkyl, or with one substituent selected from chloro, fluoro, and phenyl optionally substituted by one chloro or fluoro; benzoxazolyl; 2-aminobenzoxazolyl; benzoxazolonyl; 2-aminobenzoxazolinyl; benzothiazolonyl; benzoimidazolonyl; and benzotriazolyl;

which comprises reacting a piperazine salt of the formula ##STR8## wherein Z is fluoro, chloro, bromo, iodo, methanesulfonate, trifluoromethanesulfonate, or trifluoroacetate; and

Ar is as defined above, with an alkyl halide containing compound of the formula ##STR9## wherein n, X and Y are as defined above and Hal is fluoro, chloro, bromo or iodo, in water with a reagent to neutralize the hydrohalic acid, heating the mixture under conditions which are suitable to effect the coupling of said piperazine salt with said alkyl halide containing compound and, if desired, preparing the corresponding pharmaceutically acceptable acid addition salt.

2. A process according to claim 1 wherein the piperazine salt is a hydrochloride or triflate salt.

3. A process according to claim 1 wherein from about one to five molar equivalents of a neutralizing agent based on the substrate not present in excess is used with from about three to ten volumes of water based on the weight of the substrate not present in excess.

4. A process according to claim 3 wherein about three molar equivalents of a neutralizing agent and about five volumes of water are used.

5. A process according to claim 4 wherein the neutralizing agent is selected from the group consisting of alkali metal carbonates, alkaline earth metal carbonates, bicarbonates, hydrides and tertiary amines.

6. A process according to claim 5 wherein the neutralizing agent is sodium carbonate.

7. A process according to claim 6 wherein the piperazine salt, alkyl halide containing compound, sodium carbonate, and water are combined and heated to reflux.

8. A process according to claim 1 wherein the mixture is heated to about reflux temperature.

9. A process according to claim 8 wherein the temperature of reflux is about 100.degree. C.

10. A process according to claim 1 wherein the compound of the formula I is 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2H-indol-2-one.

11. A process according to claim 10, comprising the step of reacting the compound of formula I with aqueous hydrochloric acid to form 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2H-indol-2-one hydrochloride monohydrate.

12. A process according to claim 1 which comprises reacting the piperazine salt with the alkyl halide containing compound in water and a neutralizing agent; refluxing the mixture for at least about 8 to 16 hours; cooling the mixture and filtering off the product.

13. A process according to claim 12 wherein from about one to five molar equivalents of a neutralizing agent based on the substrate not present in excess is used with from about three to ten volumes of water based on the weight of the substrate not present in excess.

14. A process according to claim 13 wherein about three molar equivalents of a neutralizing agent and about five volumes of water are used.

15. A process according to claim 14 wherein the neutralizing agent is sodium carbonate.

16. A process according to claim 15 wherein the piperazine salt, alkyl halide containing compound, sodium carbonate and water are combined and heated to reflux.

17. A process according to claim 16 wherein the temperature of reflux is about 100.degree. C.

18. A process according to claim 12 wherein the compound of formula I is 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2H-indol-2-one.

19. A process according to claim 18 comprising the step of reacting the compound of formula I with aqueous hydrochloric acid to form 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2H-indol-2-one hydrochloride monohydrate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc